<DOC>
	<DOCNO>NCT01818596</DOCNO>
	<brief_summary>This open-label , multicenter , multi-cohort study ass safety , tolerability , efficacy elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide ( Genvoya® ; E/C/F/TAF ) fixed-dose combination ( FDC ) tablet treatment-naive treatment-experienced HIV-positive , adult participant mild moderate renal impairment . The primary objective study evaluate effect E/C/F/TAF renal parameter Week 24 . The proportion subject achieve virologic response HIV-1 RNA &lt; 50 copies/mL also assess . At site able conduct appropriate testing , approximately 30 participant enrol intensive pharmacokinetic/pharmacodynamic ( PK/PD ) substudy evaluate PK/PD parameter individual component E/C/F/TAF well tenofovir diphosphate ( TFV-DP ) .</brief_summary>
	<brief_title>Open-label Safety Study E/C/F/TAF ( Genvoya® ) HIV-1 Positive Patients With Mild Moderate Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Key Cohort 1 ( treatmentexperienced switch ) Must history know resistance elvitegravir ( EVG ) , tenofovir disoproxil fumarate ( TDF ) , emtricitabine ( FTC ) Plasma HIV1 RNA concentration ( least two measurement ) undetectable level ( accord local assay use ) 6 month precede screen visit HIV1 RNA &lt; 50 copies/mL screening Estimated glomerular filtration rate ( GFR ) 3069 mL/min accord CockcroftGault formula creatinine clearance , use actual weight May currently enrol Gilead study GSUS2360102 , GSUS2360103 , GSUS2160114 , eligible enroll Week 144 visit study complete ; currently receive Stribild® ( STB ) atazanavir ( ATV ) /cobicistat ( COBI ) + Truvada ( TVD ) Gilead study GSUS2360104 GSUS2160105 , eligible enroll Week 48 visit study complete . Cohort 2 ( treatmentnaive ) Plasma HIV1 RNA level ≥ 1,000 copies/mL screen Screening genotype report provide Gilead Sciences must show sensitivity EVG , FTC , TDF No prior use approved investigational antiretroviral drug length time , except use preexposure prophylaxis ( PrEP ) , postexposure prophylaxis ( PEP ) , 6 month prior screen Estimated GFR 3069 mL/min accord Cockcroft Gault formula creatinine clearance , use actual weight All Cohorts : All subject must meet follow inclusion criterion eligible participation study : The ability understand sign write informed consent form , must obtain prior initiation study procedure CD4+ count ≥ 50 cells/μL Stable renal function : serum creatinine measurement take least ( within three month screen ) Cause underlie chronic kidney disease ( eg hypertension , diabetes ) stable , without change medical management , 3 month prior baseline Normal electrocardiogram ( ECG ) Hepatic transaminase ( AST ALT ) ≤ 5 x upper limit normal ( ULN ) Total bilirubin ≤ 1.5 mg/dL , normal direct bilirubin Adequate hematologic function Serum amylase ≤ 5 x ULN Females childbearing potential must agree utilize highly effective contraception method ( two separate form contraception , one must effective barrier method , nonheterosexually active , practice sexual abstinence ) screen throughout duration study treatment 30 day follow last dose study drug Female subject utilize hormonal contraceptive one birth control method must use method least three month prior study dose Male subject must agree utilize highly effective method contraception heterosexual intercourse throughout study period 30 day follow discontinuation investigational medicinal product . A highly effective method contraception define two separate form contraception , one must effective barrier method , male subject must nonheterosexually active , practice sexual abstinence Age ≥ 18 year Key A new AIDSdefining condition ( exclude CD4 cell count percentage criterion ) diagnose within 30 day prior screen , exception first two bullet point Hepatitis C virus ( HCV ) antibody positive . Subjects HCV positive , documented negative HCV RNA , eligible Hepatitis B surface antigen ( HBVsAg ) positive Subjects receive drug treatment Hepatitis C , subject anticipate receive treatment Hepatitis C course study Subjects experience decompensated cirrhosis ( eg , ascites , encephalopathy , etc . ) Females breastfeed Positive serum pregnancy test Have implant defibrillator pacemaker Current alcohol substance use judge Investigator potentially interfere subject study compliance A history malignancy within past 5 year ongoing malignancy cutaneous Kaposi 's sarcoma , basal cell carcinoma , resect , noninvasive cutaneous squamous carcinoma Active , serious infection ( HIV1 infection ) require parenteral antibiotic antifungal therapy within 30 day prior baseline Subjects hemodialysis , form renal replacement therapy , treatment underlie kidney disease ( include prednisolone dexamethasone ) Subjects receive ongoing therapy medication use EVG , COBI , FTC , TAF subject know allergy excipients E/C/F/TAF Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>HIV</keyword>
	<keyword>HIV-1 Infected</keyword>
	<keyword>Treatment Experienced</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>